Breast cancer male

7 clinical trials

Quick filters

Clinical trials for Breast cancer male

7 trials across Europe

See all trials →

Quick filters

7 Clinical trials

Triple negative breast cancer+4

Recruiting

Registered drugNo placebo

Neoadjuvant Sacituzumab Govitecan and Pembrolizumab for Patients with Clinical Stage II-III Triple-Negative Early Breast Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:WSG Women's Cancer Study Group GmbH

Contact Research Centre

Breast cancer+4

Recruiting

Registered drugNo placebo

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Elacestrant
Sponsor:WSG Women's Cancer Study Group GmbH

Contact Research Centre

Triple negative breast cancer+4

Recruiting

Registered drugNo placebo

Study Comparing Sacituzumab Govitecan Alone and with Pembrolizumab for Patients with Low-Risk, Triple-Negative Early Breast Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:WSG Women's Cancer Study Group GmbH

Contact Research Centre

Endometrial cancer+38

Recruiting

InvestigationalNo placebo

Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Ds-3939A
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Breast cancer+4

Not recruiting

Registered drugNo placebo

Study of Pembrolizumab and Olaparib for Patients with Advanced HER2 Negative Breast Cancer and Specific Genetic Mutations

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Olaparib
Sponsor:Institut fuer Frauengesundheit GmbH

Contact Research Centre

Breast cancer+7

Not recruiting

Registered drugNo placebo

Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:GBG Forschungs GmbH

Contact Research Centre

See all trials →

Breast cancer male

Clinical trials for Breast cancer male

Triple negative breast cancer+4

Neoadjuvant Sacituzumab Govitecan and Pembrolizumab for Patients with Clinical Stage II-III Triple-Negative Early Breast Cancer

Breast cancer+4

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Triple negative breast cancer+4

Study Comparing Sacituzumab Govitecan Alone and with Pembrolizumab for Patients with Low-Risk, Triple-Negative Early Breast Cancer

Endometrial cancer+38

Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors

Breast cancer+4

Study of Pembrolizumab and Olaparib for Patients with Advanced HER2 Negative Breast Cancer and Specific Genetic Mutations

Breast cancer+7

Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Filter the trials

Prefer not to search? Our Concierge searches the trials for you.